Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 7% – Should You Sell?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) shares fell 7% during trading on Tuesday. The company traded as low as $21.60 and last traded at $21.6310. 178,281 shares traded hands during mid-day trading, a decline of 26% from the average daily volume of 240,852 shares. The stock had previously closed at $23.25.

Analysts Set New Price Targets

Several research firms have recently commented on FTH. JonesTrading started coverage on Sensei Biotherapeutics in a research note on Tuesday, August 4th. They issued a “buy” rating and a $55.00 target price for the company. TD Cowen assumed coverage on Sensei Biotherapeutics in a research note on Wednesday, September 9th. They set a “buy” rating on the stock. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, September 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $56.25.

Sensei Biotherapeutics Trading Down 6.7%

The firm has a market cap of $560.60 million, a P/E ratio of -0.15 and a beta of -0.29. The firm has a 50-day moving average of $31.75.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($5.04) by $2.20. On average, sell-side analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current fiscal year.

Institutional Trading of Sensei Biotherapeutics

A number of institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new stake in shares of Sensei Biotherapeutics during the 2nd quarter valued at $307,000. Renaissance Technologies LLC lifted its stake in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the period. Bank of America Corp DE lifted its stake in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics in the 2nd quarter worth $3,610,000. Finally, Stempoint Capital LP bought a new position in shares of Sensei Biotherapeutics in the 1st quarter worth $4,188,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.